| Status: Recommended | |||
Glecaprevir / pibrentasvir (Maviret®) granules are recommended as an option for use within NHS Wales, for the treatment of chronic hepatitis C virus (HCV) infection in children aged 3 years to < 12 years, and glecaprevir / pibrentasvir (Maviret®) tablets are recommended as an option for use within NHS Wales for those aged 12 years to less than 18 years. |
|||
|
|||
Medicine details |
|||
| Medicine name | glecaprevir / pibrentasvir (Maviret®) | ||
| Formulation | 50 mg / 20 mg coated granules in sachet, 100 mg / 40 mg film-coated tablets | ||
| Reference number | 4917 | ||
| Indication | Treatment of chronic hepatitis C virus (HCV) infection in children and adolescents aged 3 years to <18 years |
||
| Company | Abbvie Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Licence extension for paediatric use | ||
| Status | Recommended | ||
| Advice number | 1521 | ||
| AWMSG meeting date | 09/11/2021 | ||
| Date of issue | 24/11/2021 | ||
| Further information This advice incorporates and replaces the AWMSG recommendation for glecaprevir / pibrentasvir (Maviret®) as an option for use in NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to < 18 years (advice number 1319, originally published 29/10/2019) |
|||